Health Care & Life Sciences » Biotechnology | Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
34,598.00
43,002.00
36,676.00
38,023.00
35,458.00
26,615
Depreciation, Depletion & Amortization
20.00
29.00
27.00
11.00
9.00
9
Other Funds
4,268.00
2,694.00
2,937.00
5,177.00
3,302.00
2,829
Funds from Operations
30,310.00
40,279.00
33,712.00
32,835.00
32,147.00
23,777
Changes in Working Capital
7,113.00
2,902.00
5,019.00
4,127.00
3,995.00
627
Net Operating Cash Flow
37,423.00
43,181.00
38,731.00
36,962.00
36,142.00
24,404
Capital Expenditures
-
48.00
-
-
26.00
Purchase/Sale of Investments
32,216.00
3,373.00
1,247.00
14,999.00
29,774.00
Net Investing Cash Flow
32,216.00
3,325.00
1,247.00
14,999.00
29,748.00
Issuance/Reduction of Debt, Net
7,182.00
9,356.00
1,642.00
6,751.00
7,615.00
Net Financing Cash Flow
5,388.00
46,921.00
42,184.00
33,131.00
25,315.00
Net Change in Cash
181.00
7,065.00
4,700.00
18,830.00
18,921.00
Free Cash Flow
37,423.00
43,229.00
38,731.00
36,962.00
36,168.00
Change in Capital Stock
12,570.00
56,277.00
43,826.00
26,380.00
32,930.00

About Sunesis Pharmaceuticals

View Profile
Address
395 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.sunesis.com
Updated 07/08/2019
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.